ASTELLAS

📅 Upcoming

🕒 Recent(90d)

News

• Supernus, Indivior merger expected to result in ‘natural redundancies’
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 13h ago
• AI data becomes sticking point in biopharma dealmaking
  As drug hunting gets more complex, where and how data is generated in partnerships between Big Pharmas and AI biotechs is becoming a headache for dealmakers.
  biospace · 13d ago
• ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
  For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…
  fiercebiotech · 14d ago
• Agenus surges on study pivot; Apnimed lines up an IPO
  Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
  biopharma_dive · 22d ago
• Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
  Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…
  biopharma_dive · 2mo ago
• STAT+: Top U.S. officials pressured Germany to pay more for prescription drugs
  It's a key piece of Trump's effort to secure lower drug prices for U.S. patients.
  stat · 2mo ago
• AstraZeneca follows Merck with Phase 3 win in bladder cancer
  A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek appr…
  endpoints · 2mo ago
• STAT+: Drug meant to make gene therapy safer may also make it less effective
  Encoded Therapeutics gives a heads-up to other gene therapy company about the trade-offs with a drug meant to improve safety.
  stat · 2mo ago
• STAT+: Why Marty Makary was the worst FDA commissioner in 25 years
  Marty Makary, who resigned under pressure from the FDA, brought to the job a fundamental lack of understanding of the nature of the role, STAT's Matthew Herper writes.
  stat · 2mo ago
• STAT+: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
  Food and Drug Administration Commissioner Marty Makary is resigning from his role after a tumultuous tenure.
  stat · 2mo ago